Anika Therapeutics ANIK Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$11.17M+80.2% | -$56.39M+31.8% | -$82.67M-456% | -$14.86M— | ||
| $5.37M-22.0% | $6.88M+7.0% | $6.43M-4.0% | $6.7M+3.5% | ||
| $10.08M-23.2% | $13.13M-13.9% | $15.24M+6.5% | $14.32M+29.1% | ||
| -$7K— | —— | -$6.33M-20.1% | -$5.27M-198% | ||
| —— | -$2.86M— | —— | $0— | ||
| —— | —— | —— | $5.63M— | ||
| —— | —— | $11.4M+65.8% | $6.87M-3.4% | ||
| $42K+102% | -$2.51M— | —— | $1.97M+279% | ||
| —— | —— | $1.65M— | —— | ||
| -$2.33M— | —— | —— | —— | ||
| —— | $665K— | —— | —— | ||
| $2.06M-4.1% | $2.15M-3.6% | $2.23M+20.6% | $1.85M+8.3% | ||
| $11.19M+107% | $5.4M— | —— | $4.41M-47.5% | ||
| $6.83M-11.7% | $7.73M+42.5% | $5.43M-27.5% | $7.49M+45.6% | ||
| —— | $0— | $0— | —— | ||
| —— | -$8.33M-53.6% | -$5.43M+27.5% | -$7.49M-140% | ||
| —— | $10.91M+118% | $5M— | —— | ||
| $1.57M-39.7% | $2.6M+20.4% | $2.16M+131% | $935K+92.4% | ||
| -$10.73M+15.7% | -$12.73M-91.0% | -$6.67M— | —— | ||
| —— | -$48K— | —— | -$130K— | ||
| —— | -$15.71M— | —— | —— | ||
| $1.08M-73.1% | $3.99M+28.1% | $3.12M+2,841% | $106K-91.4% | ||
| —— | —— | —— | —— | ||
| -$2.33M— | —— | —— | —— | ||
| $5.82M-87.0% | $44.71M+1,238% | $3.34M-37.3% | $5.33M+8.7% | ||
| $2.06M-4.1% | $2.15M-3.6% | $2.23M+20.6% | $1.85M+8.3% | ||
| $1.33M— | —— | $0— | —— | ||
| —— | $0— | $0— | —— | ||
| $357K-71.1% | $1.24M-84.1% | $7.78M0.0% | $7.78M-0.7% | ||
| —— | —— | —— | —— | ||
| —— | -$48K— | —— | -$130K— | ||
| -$2M+4.1% | -$2.08M+3.1% | -$2.15M-44.7% | -$1.49M+8.7% | ||
| $896K— | $0— | $0— | —— | ||
| $0-100% | $5.94M— | $0— | $0— | ||
| $265K-77.6% | $1.19M— | —— | $379K+492% | ||
| $1.08M-73.1% | $3.99M+28.1% | $3.12M+2,841% | $106K-91.4% | ||
| $4.36M— | —— | —— | —— | ||
| $4.36M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Anika Therapeutics generate?
- Anika Therapeutics (ANIK) generated $6.5M in operating cash flow over the trailing twelve months.
- What is Anika Therapeutics's free cash flow?
- After $5.4M of capital expenditures, Anika Therapeutics's free cash flow was $1.0M over the trailing twelve months, up 105.4% year over year.
- Where does Anika Therapeutics's cash flow data come from?
- Every line is extracted from Anika Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
